Mechanism of inhibitation of human leukocyte elastase by benzisothiazolinone-1,1-dioxides by Franke, Catherine




Mechanism of inhibitation of human leukocyte
elastase by benzisothiazolinone-1,1-dioxides
Catherine Franke
Follow this and additional works at: http://scholarworks.rit.edu/theses
This Thesis is brought to you for free and open access by the Thesis/Dissertation Collections at RIT Scholar Works. It has been accepted for inclusion
in Theses by an authorized administrator of RIT Scholar Works. For more information, please contact ritscholarworks@rit.edu.
Recommended Citation
Franke, Catherine, "Mechanism of inhibitation of human leukocyte elastase by benzisothiazolinone-1,1-dioxides" (1995). Thesis.
Rochester Institute of Technology. Accessed from





SUBMITTED IN PARTIAL FULFILLMENT OF THE





Rochester Institute of Technology
Rochester, New York 14623
Department of Chemistry
STATEMENT FOR GRANTING ORDENYING PERMISSION TO REPRODUCE
THESIS
Title ofThesis. MECHANISM OF INHIBITION OF HUMAN LEUKOCYTE
ELASTASE BY BENZISOTHIAZOLINONE-l,l-DIOXH)ES
I, Catherine A. Franke, hereby grant permission to theWallaceMemorial Library, of
R.I.T., to reproduce my thesis in whole or in part. Any reproduction will not be for
commercial use or profit.









HLE Substrate Specificity and CatalyticMechanism 3
Inhibitors ofHLE 7
Transition state analog inhibitors 7





Determination ofHLE inhibition constants. 23
Titration of active HLE. 25
Stopped-flow analysis ofHLE inactivation. 25
Secondary deuterium isotope effects on inactivation kinetics. 26
HPLC analysis ofproducts formed during reactivation. 27
Secondary deuterium isotope effects on reactivation kinetics. 28
Inhibition ofHLE-catalyzed elastin degradation by alpha- 1 -protease inhibitor and 28
13
RESULTS and DISCUSSION 30
Inhibition Studies. 30
Inhibition ofHLE-catalyzed hydrolysis of insoluble elastin. 33
Reactivation rates. 35
HPLC Analysis ofProducts Following Reactivation. 36
Inactivation pathway. 41
Secondary deuterium isotope effects on inactivation. 45




Figure 1 : Serine Protease Mechanism 5
Figure 2: Scheme for binding transition state analog inhibitors a) peptide 8
trifluoromethyl ketone binding; b) peptide boronic acid binding




Figure 4: Proposed mechanism of enzyme acylation for benzoxazinones 1 1
Figure 5: Pathways for deacylation of benzoxazinone inhibited enzyme 12
Figure 6: Reaction of HLE with peptide chloromethyl ketone. The side chain 14
of the P1 residue of the inhibitor is shown interacting with the primary
binding subsite of the enzyme.
Figure 7: Proposed mechanism of inhibition of HLE by 3-alkoxy-7- amino-4- 17
chloroisocoumarins
Figure 8: Proposed chemical mechanism for the inhibition of HLE by the 18
cephalosporin derivatives. The ratio of A:B represents the partion ratio.
Pathway A regenerates active enzyme. Pathway B produces the stable,
inhibited enzyme complex
Figure 9: Catalytic mechanism proposed for the inhibition of HLE by 19
monocyclic .8-lactams
Figure 10: Progress curves for the hydrolysis of substrate in the presence of 30
13
Figure 1 1 : Kinetic analysis of 13 using Stopped-Flow Spectroscopy 31
Figure 12: Plot to determine the final Kj where Vi is the slope in the absence 33
of inhibitor and vf is final slope from Figure 10.
Figure 13: Inhibition of HLE catalyzed elastinolysis by 13 and by alpha-1- 34
proteinase inhibitor
Figure 14: HPLC analysis of products of reactivation of the HLE-inhibitor 37
complex
Figure 1 5: UV spectra of ring-closed standard and product of reactivated 38
m
HLE-inhibitor complex
Figure 16: Proposed mechanism of inhibition of HLE 40
Figure 1 7: Spectra from the stopped-flow analysis of the reaction of inhibitor 41
14 with HLE in the presence of substrate.
Figure 18: Stopped-flow kinetics of phenol release from 14 42
Figure 19: Stopped-flow kinetics, p-nitroaniline release in the absence of 43
inhibitor and in the presence of 14
Figure 20: Limited solubility model assumes that HLE does not react with 46
inhibitor in Brij35 micelles
Figure 21 : Simulation of limited solubility model with fit to slow-binding 48
kinetic equation
Figure 22: Simulation of limited solubility model with fit to slow-binding 48
kinetic equation
Figure 23: HLE activity during reactivation by deuterated (filled) and non- 51
deuterated (open) inhibitor 20
Index of Tables
Table 1 : Kinetic Constants for Inhibition of HLE 32
Table 2: Rate of Enzyme Reactivation is Dependent on R4 and R6 36
Substituents
Table 3: Rate of Enzyme Reactivation is Independent of Leaving Groups 36
(LG)
Table 4: Kinetics of inhibition of HLE by 14. Monitored by substrate and by 44
phenol release in the presence of BSA
Table 5: Stopped-Flow Kinetics of HLE inhibition in the presence of Brij35 45
Table 6: Phenol Release in Brij35 46
IV
Acknowledgements
I would like to acknowledge several individuals whose support and encouragement have helped
me a great deal in completing this thesis. I would like to especially thank Rich Dunlap, a friend
and a mentor who has always believed in me, and who patiently encouraged and helped me every
step of the way. The emotional support and thoughtful insight he has given me throughout this
entire experience have been incredibly important. My life has truly been enriched through his
friendship and guidance. A special thanks to Al Mura for his synthetic efforts in supplying the
deuterated compounds used to determine the secondary isotope effects, for reviewing this
manuscript, and for his many helpful suggestions. Finally, I would like to express my appreciation
to the synthetic chemists of the elastase inhibitor project team for providing the compounds used
in support of this thesis.
Abstract
Benzisothiazolinone-1,1 -dioxides are potent, time-dependent, reversible inhibitors of human
leukocyte elastase (HLE) that demonstrate the ability to inhibit HLE catalyzed degradation of
insoluble elastin. A stoichiometry of 1.4 to 1.47 equivalents per mole of enzyme indicates that
these compounds are efficient inhibitors ofHLE. The proposed mechanism ofHLE inhibition has
been investigated and the data are consistent with acylation of the active site serine followed by
elimination of the leaving group to form a reactive sulfonyl imine intermediate. The reactive
intermediate can undergo hydration followed by deacylation or it can react with an enzyme
nucleophile to form a stable enzyme-inhibitor complex that slowly reactivates. Initial velocities in
the presence and absence of inhibitor are identical, establishing that the reversible formation of a
Michaelis complex does not occur prior to covalent interaction between the enzyme and inhibitor.
The leaving group is released in a kinetically competent step without an induction period. The
lack of a secondary deuterium isotope effect on inactivation kinetics is consistent with rate
limiting forward acylation. Reactivation is independent of leaving group variations, suggesting the
formation of a common enzyme-inhibitor complex and a common reactivation pathway through
the same rate determining step. The product of reactivation is the 4-isopropyl-6-
methoxysaccharin. Initially, 30% forms within 5 minutes while the remainder forms slowly over 4
days. This is consistent with partitioning between reactivation and crosslinking the enzyme active
site serine and histidine. Even the crosslinked enzyme has an important reactivation pathway
whereby the enzyme regains full activity. Thus, this class of compounds may offer several
advantages over other types ofHLE inhibitors as potential therapeutic agents in the treatment of
inflammatory pulmonary diseases.
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MECHANISM OF INHIBITION OF HUMAN LEUKOCYTE ELASTASE BY
BENZISOTHIAZOLINONE-1,1 -DIOXIDES
INTRODUCTION
Human leukocyte elastase (HLE) is a serine protease that has been implicated as the principal
pathogenic agent in several inflammatory airway diseases, including pulmonary emphysema,
chronic bronchitis, adult respiratory distress syndrome (ARDS), and cystic fibrosis (JanofF, 1985;
Tetley, 1993; Wewers, 1989). HLE is normally present in the azurophilic granules of human
neutrophils and is essential for a number of important physiological processes, particularly
phagocytosis. Neutrophils release active elastase and other proteolytic enzymes, including
cathepsin G, collegenase and oxidases, into the extracellular environment in response to
inflammatory stimuli. Elastase can be extremely destructive if not carefully regulated because it
has the ability to degrade proteins of the extracellular matrix. These include proteoglycans,
collagens, fibronectin and the important connective tissue protein of the lung, elastin (JanofF,
1985). Tissue destruction by neutrophils and the cooperative role ofHLE has been reviewed by
Weiss, 1989.
Under normal physiological conditions, the proteolytic activity of free HLE is controlled by
endogenous regulatory proteins, predominantly
alpha- 1 -protease inhibitor. The protease-
antiprotease imbalance hypothesis for the role of HLE in emphysema and related diseases has
been proposed (Janoff, 1985). An imbalance between HLE and the endogenous inhibitor, arising
from either a deficiency in effective alpha- 1 -protease inhibitor or abnormally high levels ofHLE,
is believed to be responsible for the pathogenesis of inflammatory pulmonary diseases in man
(Tetley, 1993).
Pulmonary emphysema is a disease characterized by a progressive loss of lung elasticity due to the
destruction of lung elastin and alveoli. Evidence suggests that a deficiency in alpha- 1 -protease
inhibitor disturbs the enzyme-inhibitor balance and the increased HLE activity ultimately leads to
the severe degradation of lung connective tissues. Support for the involvement of HLE in
emphysema is the observation that individuals genetically deficient in
alpha- 1 -protease inhibitor
have 10% normal inhibitor activity and are predisposed to the disease. In addition, cigarette
smoke has been shown to oxidatively deactivate
alpha- 1 -protease inhibitor. This is believed to
cause a functional deficiency of alpha- 1 -protease inhibitor in the lungs of smokers and may be a
primary factor in the development of emphysema associated with smoking (Janoff, 1985).
The same pathology based on a similar mechanism has been reported for cystic fibrosis and
chronic bronchitis, however in these disease states abnormally high levels ofHLE in the lung are
assumed to cause the imbalance (Tetley, 1993). The protective inhibitor cannot adequately inhibit
the excess free elastase present in the lung resulting in uncontrolled proteolysis. This hypothesis is
supported by the observations that increased HLE activity is found in sputum of cystic fibrosis
patients and airways of bronchitis patients. The possible role of increased amounts of HLE in
ARDS and the relationship with other pulmonary diseases has also been reviewed (Wewers,
1989).
The importance ofHLE in the pathogenesis of these debilitating diseases has made this enzyme
the focus of extensive investigation, particularly in the development of potent and specific
inhibitors. An inhibitor of HLE should be an effective therapeutic agent for the treatment of
emphysema and inflammatory pulmonary diseases. Inhibitors could be natural protein inhibitors
isolated from animal or plant sources, however there are several disadvantages associated with
large protein inhibitors. They must be given by injection or inhalation and the possibility of
immunogenicity exists. They are also more difficult to obtain in large quantities. An alternative
that has attracted considerable interest is the design of synthetic low molecular weight inhibitors.
These can be synthesized in large quantities and have the potential to be orally active. Also,
structural modifications may lead to increased reactivity and selectivity or reduced toxicity. A
number of synthetic low molecular weight inhibitors of HLE have been reviewed (Stein et ah,
1985; Trainor, 1987; Powers etal, 1986).
HLE Substrate Specificity and Catalytic Mechanism
The design of potent, synthetic inhibitors ofHLE and elucidation of their mechanism of action
requires an understanding of the substrate specificity of the enzyme and the catalytic mechanism
by which the enzyme operates. HLE is a strongly basic glycoprotein with a molecular weight of
33,000 daltons. It is a single peptide chain of 218 amino acid residues and four disulfide bridges.
This enzyme exists as several distinct isozymes that display identical enzymatic activity and differ
only in carbohydrate content (Green et ah, 1991). HLE is an endopeptidase that preferentially
cleaves peptide linkages between non-ionic amino acids where the
P1
amino acid residue has a
small alkyl side chain such as valine and alanine (Schecter, I. and Berger, A., 1967). The side
chain of the
P1
residue binds into the primary specificity pocket (S1) of the enzyme. This pocket is
hydrophobic in character and can best accommodate small aliphatic side chains. In addition, the
enzyme has an extended substrate binding pocket that contains an abundance of hydrophobic
amino acid side chains. This site recognizes a number of amino acid residues on both sides of the
scissile bond. This recognition extends to the
P5
residue in the N-terminal direction and to the
P3'
residue in the C-terminal direction (McRae et ah, 1980; Nakajima et ah, 1979). Interactions at
remote subsites can profoundly influence the catalytic efficiency and specificity of the enzyme
(Stein, 1985). The primary and tertiary structures of HLE determined by X-ray crystallography
and its substrate specificity have been reviewed by Bode et ah, 1989.
In all serine proteases the catalytic site is composed of a triad of amino acid residues. The
uniquely reactive hydroxyl group of serine-195, the imidazole group of histidine-57 and the
carboxylate group of aspartic
acid-102 are the critical components of the active site that perform
the peptide bond hydrolysis, presumably by a general base catalyzed reaction. This class of
enzymes is also characterized by the presence of an oxyanion hole made up of two backbone
amide hydrogens ofglycine-193 and serine-195 that stabilize the negative charge on the transition
state formed during catalysis. The general reaction catalyzed by serine proteases is essentially an
acyl transfer reaction involving the formation and subsequent hydrolysis of an acyl enzyme
intermediate. The proposed catalytic mechanism of a serine protease shown in Figure 1 is widely
accepted (Kraut, 1977; Powers, 1986; Stryer, 1988). The first stage in the hydrolysis of the
peptide substrate is acylation where the catalytic triad and the oxyanion hole facilitate the
formation of a tetrahedral transition state leading to the formation of a covalent acyl enzyme
intermediate. Initially the imidazole group of histidine-57 acts as a general base in abstracting a
proton from the hydroxyl group of serine-195, enhancing the nucleophilicity of the serine oxygen
atom as it attacks the carbonyl carbon atom of the susceptible peptide bond to give the tetrahedral
adduct. The carboxylate group of aspartic
acid-102 facilitates the proton transfer process by





























Figure 1 : Serine Protease Mechanism
it during the transition state through electrostatic interactions. The oxyanion of the tetrahedral
transition state is stabilized by hydrogen bonding to the two main chain NH groups in the
oxyanion hole. The protonated imidazole then acts as a general acid by donating a proton to the
departing amino group. The peptide bond is cleaved, liberating the amino portion of the substrate
and the tetrahedral transition state breaks down to the acyl enzyme intermediate.
The next stage, deacylation, is mechanistically just the reverse of the acylation process with an
acyl-accepting nucleophile, such as water, replacing the amine component of the original
substrate. The hydrolysis of the acyl enzyme intermediate to active enzyme and the carboxylic
acid product occurs through an analogous reaction sequence. The imidazole removes a proton
from the attacking water molecule and donates a proton to the serine oxygen atom as it is
liberated from the tetrahedral addition intermediate.
Inhibitors ofHLE
Several types of synthetic inhibitors of HLE have been reported in the literature. These
compounds interfere with the formation of the enzyme-substrate tetrahedral adduct, the key
intermediate in normal peptide hydrolysis previously described. In general, three approaches to
the design of inhibitors have been used in an attempt to develop therapeutically useful synthetic
low molecular weight inhibitors. These include transition state analog inhibitors, alternate
substrate inhibitors and suicide inhibitors, all ofwhich bind covalently to HLE in a reversible or
irreversible fashion.
Transition state analog inhibitors
Reversible inhibitors that are peptide analogs containing aldehydic or trifluoromethyl functional
groups are effective inhibitors ofHLE. They have an electrophilic carbonyl and form reversible
covalent adducts with the enzyme, operating via a transition state inhibition mechanism. The
peptide trifluoromethyl ketones are potent, specific slow-binding inhibitors ofHLE with inhibition
constants in the nanomolar range (Dunlap, 1987; Stein et ah, 1987a; Skiles et ah, 1992).
Mechanistic studies suggest that inhibition ofHLE by trifluoromethyl ketones involves addition of
the active site serine-195 to the ketone carbonyl of the inhibitor to form a hemiketal adduct that
mimics the tetrahedral transition state intermediate in the reaction pathway for normal peptide
hydrolysis (Figure 2a). Hemiketal formation is facilitated by the strongly electron-withdrawing
trifluoromethyl functionality. The intermediate is stabilized from secondary binding interactions of
the peptide portion of the inhibitor with remote enzyme subsites. The aldehydes are believed to
inhibit HLE in a similar manner. A detailed study of the mechanism of inhibition of HLE by
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Figure 2: Scheme for binding transition state analog inhibitors a) peptide
trifluoromethyl ketone binding; b) peptide boronic acid binding (Trainor, 1987)
Peptide boronic acids are a unique group of compounds that also act as transition state analog
inhibitors ofHLE and exhibit reversible, slow-binding inhibition. The trigonal boronic acid forms
a tetrahedral covalent addition complex with the active site serine-195 that resembles the enzyme-
substrate transition state (Figure 2b). One hydroxyl group of the boronic acid occupies the
oxyanion hole and the other hydroxyl group corresponds to the position of the leaving amino
group for normal substrate hydrolysis. The best HLE inhibitor of this class, MeO
Sue-Ala-Ala-
Pro-Val-B(OH)2, has a valine residue in the
P1
site and K; = 0.6 nM (Kettner and Shenvi, 1984).
Alternate substrate inhibitors
The alternate substrate approach utilizes a substrate that inactivates the enzyme by acylation of
the strongly nucleophilic active site serine to form a stable or slowly hydrolyzed acyl enzyme. For
alternate substrates the same factors that cause slow deacylation of the enzyme will also decrease
the rate of acylation. Therefore, it is difficult to design inhibitors that have fast inactivation rates







Compounds containing a benzisothiazolone nucleus (1 and 2) have been reported to be acylating
inhibitors ofHLE (Zimmerman et ah, 1980; Ashe et ah, 1981). These inhibitors are proposed to
react with the active site serine-195, whereby the amide bond in the heterocyclic ring is cleaved,
producing a long-lived acyl enzyme (Figure 3). Of the
N-acylbenzisothiazolinone-1,1 -dioxide
class, furoyl saccharin was one of the most potent inhibitors studied, owing its effectiveness to the
extremely slow deacylation step (kdeacyiation
=
10"6
s'1). The inhibitory capacity of N-
arylbenzisothiazolinone-1,1 -dioxides is directly related to the electron-withdrawing capability of








Figure 3: Proposed mechanism of action of N-arylbenzisothiazolone-1,1 -dioxides
(Ashe, 1981)
with an inhibition constant of2.2 uM.
Substituted benzoxazinones are alternate substrate inhibitors of HLE that were designed to
achieve potency by rapid acylation combined with slow deacylation (Krantz etah, 1987; Krantz et
ah, 1990). A number of 4H-3,l,-benzoxazin-4-one inhibitors (3) have been prepared with
substituents that are known to influence carbonyl reactivity through electronic and steric effects
for optimization of compound stablility and potency. The acylation and deacylation reaction rates,
R5 0
as well as the hydrolytic stability of the benzoxazin-4-ones, can be altered by changing the nature
of the substituents in both rings. Electron-withdrawing substituents increase both the acylation
and hydrolysis rates, electron-donating substituents increase stability, and bulky substituents often
slow deacylation rates. The mechanism of enzyme acylation (Figure 4) is proposed to begin with
the formation of a Michaelis complex (E-I)i, a noncovalent species that precedes the chemical
steps. This reversible, noncovalent binding step is followed by addition of serine-195 at the
oxazinone carbonyl to form a tetrahedral intermediate (E-I)2 and then collapse of the tetrahedral
intermediate to the ring-opened acyl enzyme (E-I).
10
Deacylation is also complex as shown in Figure 5. The three pathways demonstrated for
breakdown of the acyl enzyme are O-cyclization (Li), N-cyclization (k2), and hydrolysis (k3).
Potency is significantly enhanced by 1) alkyl R5 substitution to slow deacylation rates through
steric effects on acyl enzyme derivatives and 2) 2-substituents that are small alkyl groups linked
via heteroatoms to enhance acylation and limit deacylation rates. Strong electron-donating groups
improve the compound stability by depressing the reactivity of the oxazinone ring to nucleophilic
11
attack. Combining these effects has led to the development of hydrolytically stable benzox-
azinones with potency in the nanomolar range.
Stein et ah, 1987b has reported valine-derived benzoxazinones (4) that are competitive, slow-
binding alternate substrate inhibitors of HLE. By varying the aryl substitution, an inhibition
constant of 0.5 nM was achieved (5-chloro compound). UV-visible spectral data for the
interaction ofHLE with these inhibitors is consistent with a mechanism involving initial acylation
of the enzyme with ring opening of the inhibitor to form a relatively stable acyl enzyme.




Suicide inhibitors are mechanism-based irreversible inactivators that require enzyme catalysis to
unmask a latent reactive functional group contained in the inhibitor structure, generating a
reactive intermediate. Further reaction can occur between the newly released reactive group and
the side chains of neighboring amino acid residues of the enzyme in the active site to produce an
irreversibly inhibited enzyme structure. Peptide chloromethyl ketones are effective suicide
inhibitors of HLE (Powers et ah, 1977). These inhibitors resemble normal substrates with the
exception that the scissile peptide bond has been replaced with a chloromethyl ketone functional
group. A detailed mechanistic investigation of HLE inhibition by MeOSue-Ala-Ala-Pro-Val-
CH2C1 (Stein et ah, 1986) suggests that the inactivation reaction follows the mechanism depicted
in Figure 6. HLE and the chloromethyl ketone inhibitor initially form a reversible Michaelis
complex (E-I)i followed by the interaction of the active site serine-195 with the ketone moiety of
the inhibitor to form a second more stable hemiketal intermediate (E-I)2. Kinetic data is consistent
with the direct attack of the active site histidine-57 on the methylene carbonyl of the hemiketal
with displacement of chloride anion. The irreversible alkylation of the active site histidine
produces the stable inactivated species (E-I) shown in Figure 6 with two bonds formed between
the enzyme and the inhibitor: one between serine-195 and the ketone carbonyl group of the
inhibitor and one between histidine-57 and the methylene group.
13
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Figure 6: Reaction of HLE with peptide chloromethyl ketone. The side chain of the P1
residue of the inhibitor is shown interacting with the primary binding subsite of the
enzyme. (Powers, 1986)
A wide variety ofheterocyclic structures that irreversibly inactivate HLE via a suicide mechanism
have also been reported, including substituted isocoumarins and i?-4actam derivatives. 3-Alkoxy-
7-amino-4-chloro-isocoumarins containing various substituents on the 7-amino group and in the
3-position are suicide inactivators ofHLE. These compounds contain a masked functional group
that is capable of alkylating an active site nucleophile upon enzyme acylation to form an extremely
stable crosslinked enzyme-inhibitor complex (Harper et ah, 1985). The proposed reaction
pathway depicted in Figure 7 involves the initial attack















Figure 7: Proposed mechanism of inhibition of HLE by 3-alkoxy-7-
amino-4-chloroisocoumarins (Bode, 1989)
isocoumarin carbonyl to form an acyl enzyme in which the isocoumarin ring is opened.
Elimination of chloride from the acyl enzyme releases a reactive acyl quinone imine methide at the
active site that can react with either an enzyme nucleophile such as the imidazole side chain of
histidine-57 to irreversibly inactivate the enzyme or with a solvent nucleophile to give a
reactivatable acyl enzyme. These inhibitors react
"nonstoichiometrically"
with HLE. Partitioning
between the two products decreases the efficiency of inhibition, requiring more than a single
equivalent of inhibitor to completely inactivate one equivalent of enzyme. Isocoumarins that lack
15
the 7-amino and 4-chloro groups do not form the irreversibly inactivated enzyme. While they
inhibit HLE, deacylation is fairly rapid.
A series of bicyclic iMactam derivatives of cephalosporins (5)
w
ex _
have been developed that are potent, time-dependent suicide '' ^s
inhibitors of HLE (Doherty et ah, 1986; Doherty et ah, 1990).
J~N>^^^OAc
Initial work demonstrated that effective inhibition ofHLE requires (s^QX&u
the free carboxyl group of the cephalosporin nucleus to be
5a R = MeO
esterified. A series of 7-substituted cephalosporin /-butyl esters _. _ _.
5b R - CI
were prepared and revealed that compounds having small alpha-
oriented substituents in the 7-position such as methoxy (5a) or chloro (5b) displayed the greatest
activity. In addition, the sulfones were the most active members of the series showing improved
inhibitory activity over the corresponding sulfides or sulfoxides. The effects of substitution on the
cephalosporin nucleus at the 2-position and the 3'-position have also been explored (Finke et ah,
1990; Shah etah, 1990).
In general, the cephalosporin derivatives are reported to rapidly and irreversibly inactivate HLE.
Preliminary kinetic data suggested a mechanism involving the initial formation of a reversible
Michaelis complex followed by the acyl enzyme intermediate that could subsequently hydrolyze or
undergo further modification (Doherty et ah, 1986; Green et ah, 1991). Navia et ah, 1987
proposed a "double
hit"
mechanism for the interaction of a related serine protease, porcine
pancreatic elastase (PPE), and the cephalosporin derivative, /-butyl-7-alpha-chloro
cephalosporinate, based on the X-ray crystallographic structure of the PPE-inhibitor complex in
16
which both acylation of the serine-195 and alkylation of the histidine-57 by the 3'-exocyclic











alpha-methoxycephalosporin derivatives (6 and 7) has provided evidence that this class of
inhibitors inactivates HLE according to a mechanism that is analogous to that proposed by Navia
et ah, 1987 (Figure 8) (Knight et ah, 1992a). Reaction of the active site serine with the 5-4actam
carbonyl produces a tetrahedral intermediate (8) that collapses, opening the 5-lactam ring.
Expulsion of the leaving group from the 3'- methylene gives rise to the acyl enzyme and a reactive
electrophilic site (9). Knight et ah, 1992a has proposed that an intermediate along the reaction
pathway partitions between A) deacylation by hydrolysis of the acyl enzyme to generate active
enzyme and the carboxylic acid (10) and B) Michael addition of the active site histidine to the
3'-
methylene to produce a stable linkage that crosslinks residues serine-195 and histidine-57. Knight
et ah, 1992a demonstrated that bicyclic lactams liberate
a
C-3'
group, a requirement for
Michael addition to this position. Inactivation by the cephalosporin derivatives is not efficient,
requiring 2 to 4 equivalents of
inhibitor to completely inactivate one equivalent ofHLE depending
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Figure 8: Proposed chemical mechanism for the inhibition of HLE by the cephalosporin
derivatives. The ratio of A:B represents the partion ratio. Pathway A regenerates active
enzyme. Pathway B produces the stable, inhibited enzyme complex. (Knight, 1992a)
A series of substituted monocyclic 5-lactams (11) are
R1
R2 R3
-I Hreported to be potent, specific time-dependent inhibitors of
^ Nv N
HLE (Green et ah, 1991; Firestone et ah, 1990; Knight et
0
R4
ah, 1992b; Knight et ah, 1993; Chabin et ah, 1993). The
11





























Figure 9: Catalytic mechanism proposed for the inhibition of HLE by monocyclic
B-
lactams (Chabin, 1993)
et ah, 1993), revealing a kinetic mechanism (Figure 9) similar to that reported for the inhibition of
HLE by cephalosporin derivatives. These data are consistent with initial formation of a reversible
Michaelis complex, followed by formation of a tetrahedral intermediate and acylation of the active
site serine with ring opening of the ZMactam ring. Departure of the leaving group at C-4 of the
iMactam ring produces a reactive imine intermediate. The imine partitions between hydrolysis to
regenerate active enzyme and further reaction, most likely with the active site histidine, to
produce a relatively stable enzyme-inhibitor complex. Partitioning of the intermediate is in the
range of 1.3 to 3.5 enzyme turnovers per enzyme inactivation depending on the inhibitor
19
substitution. These compounds are not true suicide inhibitors in that the final enzyme-inhibitor
complex slowly hydrolyzes to regenerate active enzyme.
Although several classes of synthetic low molecular weight compounds that are potent inhibitors
ofHLE have been developed, the specificity and oral bioavailability for these compounds have not
been entirely adequate to proceed as therapeutic agents. The peptide trifluoromethyl ketone
transition state analogs are the only class of inhibitors to be tested in man. These compounds have
the advantage of being highly selective because specificity is achieved both from slower
inactivation rates and faster reactivation rates for non-targeted enzymes. However, oral
bioavailability for these drug candidates remains elusive. The peptide aldehydes are highly
unstable in vivo and therefore are not useful as therapeutic agents. A disadvantage of suicide
inhibitors is that they lack a mechanism for enzyme reactivation for improved specificity. The
peptide chloromethyl ketones are alkylating agents that can react with a variety of nucleophiles
other than the target enzyme and therefore, have little therapeutic potential. The major limitation
to the clinical use of irreversible suicide inhibitors is that they are intrinsically reactive molecules
that may react nonspecifically and exhibit toxic effects. Incomplete specificity can potentially
cause renal or liver failure and render these inhibitors unsafe for clinical use. A potent, selective
inhibitor of HLE that is orally bioavailable remains an attractive target for the treatment of
pulmonary diseases in man.
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A new class of heterocyclic mechanism-based inhibitors of HLE, the
benzisothiazolinone-1,1-
dioxides (12) have recently been reported by Hlasta et ah, 1994. These compounds are potent,
selective time-dependent, stoichiometric inhibitors that follow a suicide mechanism to form a
crosslinked enzyme-inhibitor complex. However, unlike transition state analog or true suicide
inhibitors they also have a built-in mechanism for HLE to regain full activity. This mode of
inhibition leads to increased selectivity since specificity can be achieved from both the inactivation
and reactivation rates. The advantage that the benzisothiazolones offer over suicide inhibitors is
the potential for improved specificity and their advantage over transition state analog inhibitors is
the potential for oral bioavailability.
The present work explores the mechanism of inhibition of HLE by benzisothiazolinone-1,1-
dioxides. Our studies suggest a mechanism in which serine-195 adds to the carbonyl causing ring
scission and formation of the acyl enzyme. The leaving group (LG) is eliminated generating a
reactive intermediate with an electrophilic center in the sulfonyl imine group. The reversible
addition ofhistidine-57 to the sulfonyl imine gives a relatively stable crosslinked enzyme-inhibitor
complex. After forming the inhibited complex, these compounds were designed to have a
21
mechanism for enzyme reactivation through a pathway different from the inactivation pathway.




HLE isolated from purulent human sputum and bovine neck ligament elastin (catalog number
ES70) were purchased from Elastin Products, Incorporated. Bovine serum albumin (BSA), human
plasma alpha- 1 -protease inhibitor, N-MeOSuc-Ala-Ala-Pro-Val-CH2C1, and the elastase substrate
MeOSuc-Ala-Ala-Pro-Val-/?NA were purchased from Sigma Chemical Company. HEPES was
purchased from Aldrich Chemical Company, HPLC grade acetonitrile was obtained from J.T.
Baker and dimethyl sulfoxide (DMSO) and all other reagents and buffers were purchased from
Eastman Kodak. All reagents were used without further purification. Water was purified by the
Milli-Q water purification system from Millipore. Assay buffers were titrated to the appropriate
pH with NaOH prior to use. All substrate and inhibitor stock solutions were prepared in DMSO.
Deuterated inhibitors were obtained from Al Mura of the Eastman Kodak Company and all other
benzisothiazolinone- 1,1 -dioxide inhibitors, standards, and leaving groups were provided by the
SterlingWinthrop Pharmaceutical Research Division.
Methods.
Determination ofHLE inhibition constants.
Kinetic constants for the inhibition ofHLE were determined by a spectrophotometric assay that
monitors the absorbance of the /?-nitroaniline product liberated from the hydrolysis of the peptide
substrate
MeOSuc-Ala-Ala-Pro-Val-pNA (Km = 50 oM, Stein, 1983) at 410 nm. Assays were
automated using a Hewlett Packard Microassay Systems robot to perform dilutions, mix
reactants, and collect spectrophotometric data in a 96-well microtiter plate format. The reaction
was initiated by the addition ofHLE (2.6 nM) to a mixture of substrate (200 oM) and inhibitor
23
where final inhibitor concentrations ranged from 5 to 2500 nM. Assays were performed at room
temperature in a total volume of350 ul ofbuffer (50 mMHEPES, 500 mM NaCl, 0. 1% BSA, pH
7.8) containing 7.5% DMSO. Inhibitors displayed time-dependent inhibition and reactions were
followed for 5 hours to ensure that a steady-state velocity had been reached.
Data from reaction progress curves were analyzed according to the methods discussed by Cha,
1975 to determine the kinetic constants for HLE inhibition. The non-linear progress curves
observed in the presence of inhibitor were fit by non-linear least squares methods to the integrated
rate equation that describes a mechanism of inhibition in which the steady-state rate is reached by
a first order process. The observed absorbance (A) is given as a function of the initial velocity (v;),
the final steadystate velocity (vf) and the observed first order rate constant (kobs) for the approach
to steady state. Control assays, carried out in the absence of inhibitor, were fit by linear regression
A = vf*t + ((vi-Vf)*(l-e-**,)Vkoh. + Ao (Eq 1)
to yield control velocities (vo). Equation 1 was used to obtain the pseudo first order rate constants
(kobs) and the final steady state velocities (vr) at several inhibitor concentrations. The second order
rate constant for inactivation (kinactivati) was determined by linear regression of a plot of kobs
versus inhibitor concentration ([I]) and was corrected for the substrate concentration ([S]) and
Michaelis constant (Km) according to Equation 2, where (1 + [S]/Km)
= 5.0 under the assay
conditions.
kobs/t1]
= ^inactivation/C1 + [SJ^m) + kreactivation C^Q 2)
The inhibition constant, K*, for inhibitors was determined from the final steady state velocities
(vf) obtained from the first order progress curves. A plot of [I]/(l-Vf/v;) versus v;/vf was fit by
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linear regression to yield a slope equal to (Ki*)(l+[S]/Km) according to Equation 3. The
([I]/(l-
vjyvi))/(vj/vf)
= (Ki*)(l + [S]/Km) (Eq 3)
reactivation rates (kreaCtiVation) were calculated from the equation,
K;* = kreactiVatJon/kiactivation. The
kinetic constants determined by this procedure were reproducible with a standard deviation of+/-
10%.
Titration of active HLE.
The active site concentration of HLE stock solutions was determined by using the irreversible
inhibitor, MeOSue-Ala-Ala-Pro-Val-CH2C1, as an active site titrant. The number of equivalents of
the chloromethyl ketone inhibitor required to completely inactivate HLE was determined by
incubating 10.5 uM HLE with 2.0 to 40.0 oM inhibitor in buffer (50 mM HEPES, 0.5 M NaCl,
0.1% BSA, pH 7.8) containing 10% DMSO at 23 C The reaction solutions were incubated for
at least 1 hour to ensure complete reaction and aliquots were assayed spectrophotometrically with
the substrate MeOSuc-Ala-Ala-Pro-Val-/?NA to determine the remaining enzyme activity. It was
determined that after 1 hour preincubation no further loss of activity occurred at all levels of
inhibitor. In a typical experiment, 25 ul inhibitor were added to a cuvette containing 225 ul HLE
in buffer. Following preincubation 10 ul aliquots were added to a cuvette containing 975 ul buffer
and assayed for activity by adding 15 ul substrate (14 mM), placing the cuvette in a
thermostatically controlled cell compartment of a Hewlett Packard 8450a spectrophotometer and
monitoring absorbance changes at 410 nm. Both substrate and inhibitor were dissolved in DMSO.
Initial velocities were calculated by linear regression of the change in absorbance as a function of
time. Observed rates were compared to those of control samples incubated in the absence of
inhibitor to determine the extent of inactivation.
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Stopped-flow analysis ofHLE inactivation.
The inactivation of HLE by benzisothiazolinone-1,1 -dioxide inhibitors was also studied by
stopped-flow spectrophotometry on an Applied Photophysics SF.17MV stopped-flow
spectrometer at 24 C. For compound 14 the elimination rate was followed directly by monitoring
the formation of the phenolic leaving group spectrophotometrically at 267 run as a function of
time. The concentration of the phenol liberated during the inactivation reaction was determined on
the basis of the extinction coefficient calculated from a standard of the leaving group. The kinetics
of inhibition of the enzyme were followed simultaneously by monitoring the release of p-
nitroaniline from the substrate at 387 nm. In the stopped-flow experiments, one reaction barrel of
the instrument was filled with a solution of HLE prepared in buffer (50 mM HEPES, 500 mM
NaCl, pH 7.8) containing 0.1% BSA and 10% DMSO. The other reaction barrel was filled with a
solution containing substrate and inhibitor prepared in the same buffer system. The final reaction
concentrations were 7 or 14 uM inhibitor 14, 12.8 uM substrate, and 3.6 uM HLE. Reactions in
the absence of inhibitor and in the absence of substrate were also followed. The experimental data
were fit by non-linear regression to obtain the first order rate constant (k0t,s). The second order
rate constant was estimated based on k0bs/[I] and corrected for (1+[S]/Km). The inhibition of
HLE by compound 13 was similarly monitored by stopped-flow spectrophotometry. The final
reaction solutions contained 400 nM inhibitor, 200 uM substrate, and 100 nM HLE in buffer (50
mMHEPES, 500 mMNaCl, pH 7.8) containing 0. 1% BSA and 10% DMSO.
Secondary deuterium isotope effects on inactivation kinetics.
The secondary deuterium isotope
effect on the inhibition of HLE by compound 13 was
determined by stopped-flow spectrophotometry at 24 C. The final reaction solutions contained 1
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uM inhibitor, 100 uM substrate and 20 nM HLE in buffer (50 mM HEPES, 500 mM NaCl, pH
7.8) containing 0.1% Brij35 and 10% DMSO. The isotope effect was calculated from 19
determinations of k0bs for inactivation by the nondeuterated inhibitor and 8 determinations of
kobs for inactivation by the deuterated inhibitor. In preliminary experiments the effect ofBrij35
on the reaction mechanism was determined by running a concentration series for 13 in the Brij35-
buffer system with final inhibitor concentrations ranging from 0.28 to 10.55 uM (final substrate
and enzyme concentrations were 100 uM and 20 nM, respectively). The substrate kinetics in the
absence of inhibitor and the rate of phenol release from compound 14 were also monitored in the
Brij35-buffer system.
HPLC analysis of products formed during reactivation.
The products produced during the reactivation of HLE following complete inactivation by
compound 15 were monitored by HPLC. Stoichiometric amounts ofHLE and inhibitor 15 (330
uM) were reacted at room temperature in buffer (50 mM HEPES, 500 mM NaCl, pH 7.8)
containing 7.5% DMSO. An aliquot of the reaction solution was subjected to HPLC analysis
without further treatment after 5 minutes initially and at various times over the course of 4 days.
HPLC analysis was conducted on a 100 X 2.1 mm HP Hypersil C-18 column with a 0.1 M
ammonium acetate/ acetonitrile gradient elution system (5% acetonitrile for 3 minutes followed by
a linear gradient in 3.5 minutes to 20% acetonitrile; maintained at 20% acetonitrile for 10 minutes
followed by a final linear gradient to 100% acetonitrile in 15 minutes). The eluants were
monitored at 230 and 254 nm. The identity of the HLE-inhibitor complex generated products and
their concentrations were determined by conducting HPLC analysis of authentic standards of the
suspected products, 2-carboxy-benzenesulfonamide (17) and 4-isopropyl-6-methoxy saccharin
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(18). Both 17 and 18 were incubated in the reaction buffer and chromatographed periodically to
ensure that no decomposition occurred over the time course of the experiment.
Secondary deuterium isotope effects on reactivation kinetics.
The secondary deuterium isotope effects on reactivation kinetics were assessed by measuring the
return of catalytic activity of deuterated and non-deuterated 4-isopropyl-6-methoxy-2-
chloromethyl benzisothiazolone (19) derived HLE-inhibitor complexes. Reactivation rates were
obtained by monitoring the rate of return of activity from a completely inhibited enzyme-inhibitor
complex. This was carried out by fully inactivating the enzyme and then diluting the enzyme-
inhibitor complex. The return of activity was then monitored by periodically assaying portions of
the mixture. In a typical experiment, 0.925 mL solutions of 8.0 uM HLE in buffer (50 mM
HEPES, 500 mM NaCl, 0.1% BSA pH 7.8) were treated with either 75 ul ofDMSO or 75 ul of
0.54 mM inhibitor (19) in DMSO at 23 C. After 5 minutes the enzyme was inhibited > 98%. The
solutions of inactive enzyme and the controls were diluted 1,000 fold with buffer and incubated at
23 C. Aliquots were removed over time and assayed for activity by adding 15 ul substrate (14
mM) to 9.85 mL of the incubation mixture in a 1 cm cell thermostated at 23 C
Spectrophotometric assays were performed on a Hewlett Packard 8450a spectrophotometer at
410 nm. Enzyme activity was monitored over 4 days and the data were fit by non-linear regression
to determine the first order rate constant for the dissociation of the enzyme-inhibitor complex
(^reactivation)- Reactivation rates for both the deuterated and nondeuterated compounds were
determined in duplicate. Controls demonstrated that no loss of enzyme activity occured over the
time course of the experiment.
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Inhibition ofHLE-catalyzed elastin degradation by alpha-l-protease inhibitor and 13.
The HLE-catalyzed solubilization of elastin was determined by the procedure of Sommerhoff et
ah, 1991. A suspension of bovine neck elastin at a concentration of 20 mg/mL was prepared in
0.1 M tricine buffer containing 0.75 MNaCl and 0.1% Triton-X-100 at pH 8.0. The suspension
was stirred for 18 hours at room temperature, washed with buffer, and resuspended in fresh buffer
to give a final elastin concentration of 10 mg/mL. An aliquot of the suspension was transferred to
a 25 -mL flask and stirred continuously at 25 C. The reaction was initiated by adding HLE to a
final concentration of 0.21 uM. At various times, aliquots were removed from the reaction flask
and quenched with 0.1 M acetic acid, 4.0 M NaCl at pH 4.7. After centrifugation, the optical
density of the supernatant at 276 nm was determined on a Hewlett Packard 8450a
spectrophotometer. The change in absorbance was linear with time. The effects of 13 and alpha-l-
protease inhibitor on this reaction were determined by varying the concentration of inhibitor in the
reaction mixture. Inhibitor was added to the incubation mixture after 10 minutes at final







Benzisothiazolinone-1,1 -dioxides display time-dependent, reversible inhibition of HLE. Reaction
progress curves of the HLE-catalyzed hydrolysis of MeOSue-Ala-Ala-Pro-Val-/?NA in the
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Figure 10: Progress curves for the hydrolysis of substrate in the presence of 13. Solid
lines were calculated by non-linear least squares fit of the data to Equation 1 .
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absence of inhibitor is linear. The nonlinear progress curves reveal that inhibition ofHLE develops
slowly over time. Early in the reaction the enzyme is fully active and rapidly hydrolyzes the
substrate, but as the enzyme is inhibited the reaction with substrate slows until a final steady state
velocity is reached. The reaction follows a first order loss in enzyme activity with time and the
observed pseudo first order rate constant is dependent on inhibitor concentration. These curves
are characterized by final steady-state velocities that are significantly depressed relative to the
control. The reversible nature of the inhibitor is demonstrated by the final positive linear slope as
opposed to a final slope of zero. Initial velocities at all levels of inhibitor could not be obtained
from these data. The reversible formation of aMichaelis complex in an initial noncovalent binding


















Figure 1 1 : Kinetic analysis of 13 using Stopped-Flow Spectroscopy
100
31
declining initial velocities at increasing inhibitor concentrations. To explore this further the
kinetics ofHLE inhibition by 13 using stopped-flow spectrometry were investigated. The rapid
reaction kinetics illustrated in Figure 11 clearly demonstrate that the initial velocity at high
inhibitor concentration is equal to the control velocity in the absence of inhibitor. The observation
that the initial velocities in the presence and absence of inhibitor are identical establishes that no
reversible formation of a noncovalent Michaelis complex occurs under the conditions of the
experiment.
Several benzisothiazolone- 1,1 -dioxides were studied and found to be potent inhibitors of HLE.
The kinetic constants for inhibition of HLE by several 4-isopropyl-6-methoxy derivatives are
reported in Table 1. The inhibition constant (Kj*) for 13 calculated from final steady-state
velocities ofFigure 10 and corrected for the concentration of substrate used in the assay is 0.014






Table 1: Kinetic Consitants for Inhibition ofHLE
Inhibitor 13 Inhibitor 14 Inhibitor 15




























Figure 12: Plot to determine the final Kj where Vj is the slope in the absence of inhibitor
and vf is final slope from Figure 10.
inactivation (kinactivation) is 8.57 X
105
M's'1. This value is in good agreement within experimental
error with the second order rate constant for inactivation obtained from the stopped-flow kinetic
analysis (kinactivation = 9.0 X
105
M's'1). Inhibition constants for compounds 14 and 15 are 0.062
and 0.01 1 nM, respectively.
Inhibition ofHLE-catalyzed hydrolysis of insoluble elastin.
The hydrolysis of elastin in the presence and absence of inhibitor is presented in Figure 13. The
ability of compound 13 to inhibit HLE hydrolysis of insoluble
elastin is compared to that of the
endogenous regulatory protein, alpha-l-protease inhibitor. In these experiments, the reaction was
initiated by combining HLE with insoluble bovine ligament elastin followed 10 minutes later by
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the addition of varying amounts of the inhibitors. This plot shows equal inhibition of elastin
degradation by alpha-l-protease inhibitor and by compound 13 at equal molar concentrations of
0.25, 0.41, and 0.81 uM. Compound 13 was as effective as alpha-l-protease inhibitor in reducing
the ongoing destruction of insoluble elastin by HLE even after binding of the enzyme to its target
substrate. These compounds are potent inhibitors ofHLE that not only effectively inhibit
HLE-
catalyzed hydrolysis of specific small peptide substrates, but also effectively inhibit the ongoing
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The enzyme kinetic data for a series of inhibitors 16a to 16d that have the same
phenylmercaptotetrazole (PMT) leaving group, but differ structurally based on the R4 and Rg
substituents on the benzisothiazolone ring are shown in Table 2. The reactivation rates vary by 10
fold for this compound series with the 4-isopropyl-6-methoxy and 4-ethyl derivatives displaying
reactivation rates of 1.2 x 10-5 s_1 and 1.26 x 10"4 s"1, respectively. In Table 3 the effect of
leaving group modifications on the reactivation rate is shown. The enzyme kinetic data for a series
of inhibitors having the same 4-isopropyl-6-methoxy nucleus, but different leaving group are
presented. The inhibition constants, Kj*, (and also kjnactiVation) varv by more than 20 fold (0.01 1
to 0.270 nM), but the reactivation rates are essentially identical (1.1 X
10"^ to 1.2 X 10"^ s_1) for
all leaving groups; PMT, dichlorobenzoate (DCB) and chloro. These structure activity
relationships show that the reactivation rate of inhibited HLE varies depending on the ring
substituents, but is independent of the leaving group present. The observation that the identity of
the leaving group does not affect the rate of enzyme reactivation suggests that the reactivation
pathway involves a common intermediate after departure of the leaving group. These results are
consistent with an inhibition mechanism in which the inactivation and reactivation pathways are
different since the substituents on the benzisothiazolone ring independently affect the inactivation
and reactivation rates. The reactivation rates remain constant for inhibitors that have the same
nucleus and vary only in the leaving group. These data suggest that the benzisothiazolone
compounds with different leaving groups form the same enzyme-inhibitor complex and that
reactivated HLE forms by the same mechanism through the same rate determining step.
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Table 2: Rate of Enzyme Reactivation is Dependent on R4 and Re Substituents
R4 0
16
R4 R6 Ki* (nM) ^reactivation
(s1) X
103
16a H H 15 0.084
16b Et H 2.0 0.126
16c i-Pr H 0.3 0.028
16d /-Pr MeO 0.27 0.012
Table 3: Rate of Enzyme Reactivation is Independent of Leaving Groups (LG)





HPLC Analysis ofProducts Following Reactivation.
The final products observed during the reactivation of
benzisothiazolinone- 1,1 -dioxide derived
HLE-inhibitor complexes were identified by HPLC analysis following complete inactivation of
HLE in the presence of equivalent amounts of inhibitor (15). A typical HPLC chromatogram of
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the reactivation reaction monitored at 230 nm is presented in Figure 14. The major product 18
formed from the dissociation of the enzyme-inhibitor complex elutes at 5.14 minutes. The identity
of this species, as well as the minor product 17, was confirmed by HPLC analysis of authentic
materials. The addition of awater molecule to the enzyme-inhibitor complex might be expected to
result in the hydrolysis of the acyl enzyme to yield the ring opened product, 2-carboxy-
benzenesulfonamide (17), and active enzyme. Deacylation is a likely pathway and is typically
observed in reactions of HLE with similar small heterocyclic compounds. Another possible
pathway leads to the ring closed product, 4-isopropyl-6-methoxysaccharin (18) which requires
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Figure 14: HPLC analysis of products of reactivation of the HLE-inhibitor complex
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hydration of the imine, a proposed intermediate along the reaction pathway. The ring closed
compound elutes at 5.13 minutes and the ring opened compound elutes at 1.75 minutes. The
species observed during reactivation displayed an HPLC retention time identical to that displayed
by the ring closed compound. The product identity was further confirmed by UV-visible spectra
obtained from the chromatograms. In Figure 15 the UV-visible spectra of the ring closed standard
and the major reaction product of the HLE-inhibitor complex after reactivation are shown. The
UV-visible spectra of these two species are identical. Over 4 days only a small amount (<5%) of
10V
UV Spectrum of Standard
UV Spectrum of Product
;>o ^^o
Figure 1 5: UV spectra of ring-closed standard and product of reactivated HLE-inhibitor
complex
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the ring opened compound was detected during the reaction and this species was identified by
both retention time and UV-visible spectra that were identical to the authentic ring opened
material.
The amount of ring closed compound produced was monitored over time. Initially, within the first
five minutes of the reactivation reaction, 30% of the ring closed material formed and then slowly
over the next 4 days, 90% of the ring closed compound was recovered. The initial 30% yield of
ring closed product corresponds to a stoichiometry of 1.4 moles of inhibitor per mole of enzyme
and is consistent with partitioning. The simplest interpretation of the data is that the intermediate
formed during the inhibition of HLE by benzisothiazolones is the imine which then partitions
between A) addition of a water molecule to produce the ring closed compound and regenerate
active enzyme and B) addition of the active site histidine to form a covalent enzyme-inhibitor
crosslinked adduct that is relatively stable and slowly releases active enzyme and ring closed
product.
The simplest kinetic mechanism for the inhibition of HLE by benzisothiazolinone- 1,1 -dioxides
consistent with the data is shown in Figure 16. This mechanism assumes that the initial formation
of the acyl enzyme utilizes the catalytic triad of the enzyme. The reaction of inhibitor with enzyme
begins with the attack of the active site serine-195 on the carbonyl of the benzisothiazolone ring
to produce acylation of the enzyme (ki) and opening of the ring. Departure of the leaving group
(kelimination) from tne acylated enzyme-inhibitor complex forms a common reactive intermediate
that contains a highly electrophilic center in the sulfonyl imine group. Partitioning likely occurs
from the imine as shown. The k4 pathway leads directly to the formation of the ring closed
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product and active enzyme. Initially 30% of the reaction follows this route. The most likely
alternate pathway is k3 where the formation of the stable crosslinked species results from the





Figure 16: Proposed mechanism of inhibition of HLE
regenerates the imine intermediate and then through pathway k^ the remainder of the ring closed
product is formed and active HLE is released. Inhibition data, HPLC product analysis and the
observation that the reactivation of inhibited enzyme is independent of leaving group are
consistent with this proposed mechanism. The results suggest that both the active site serine and
histidine interact with the inhibitors and that k_3 is part of the reactivation pathway.
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Inactivation pathway.
The inactivation pathway was investigated further using stopped-flow analysis of the inactivation
ofHLE by compound 14. The elimination rate was followed directly by spectrophotometrically
monitoring the release of the trifluoro phenolic leaving group from inhibitor 14 at 267 nm. The
kinetics of inhibition of the enzyme by this inhibitor were followed simultaneously by monitoring
the release of /?-nitroaniline from the substrate at 387 nm. The series of spectra presented in
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Figure 17: Spectra from the stopped-flow analysis of the reaction of inhibitor 14 with
HLE in the presence of substrate.
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In stopped-flow experiments monitored over 10 s, the leaving group was released from inhibitor
14 in a first order process with k0bs =1.1
s"1
and 0.6 s"1 for inhibitor concentrations of 14 and 7
uM, respectively. Figure 18 displays a typical first order kinetic plot of phenol release from the
reaction of 3.6 uM HLE with 14 uM inhibitor. No induction period was observed for leaving
group release. The inhibition kinetics followed in the presence and absence of inhibitor 14 are
shown in Figure 19. The initial velocity of the inhibited reaction at high inhibitor concentration
(14 uM) was identical to the control velocity without inhibitor. This is consistent with the
previous stopped-flow investigation of compound 13 and with the lack of an initial binding step.
The inhibiton of HLE by compound 14 (14 uM) displayed a k^
= 1.1 s-1. The results
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Figure 19: Stopped-flow kinetics, p-nitroaniline release in the absence of inhibitor and
in the presence of 14
obtained for phenol release at two inhibitor concentrations (7 uM and 14 uM) and for
p-
nitroaniline release in the presence of 14 uM inhibitor are presented in Table 4. These data
demonstrate that the phenolic leaving group is liberated from the inhibitor at a rate similar to the
rate of enzyme inactivation.
The reaction of 3.6 uM HLE with compound 14 resulted in the formation of 5.3 to 5.4 uM
leaving group. This corresponds to an average stoichiometry of 1 .47 equivalents of inhibitor per
equivalent of HLE and is in agreement with the previous stoichiometry of 1.4 determined by
HPLC analysis. The second order rate constants were estimated from k0bs and the inhibitor
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Table 4: Kinetics of inhibition of HLE by 14. Monitored by substrate and by
phenol release in the presence of BSA
Experiment Concentration kobs (s"1) ^inactivation Phenol Ratio
to monitor of [14] uM
(M1
s'1) released (oM) [14]/[HLE]
Phenol 14 1.1 1.01
X105
5.4 1.49
Phenol 7 0.6 1.13
X105
5.3 1.45
/7-Nitroaniline 14 1.1 1.01
X105
concentration corrected for the 5.4 uM of inhibitor consumed in the reaction during the






= 7 and 14 uM, respectively. These rates are similar to the second order
rate constant for the inactivation ofHLE by this inhibitor (1.01 X
105
M'^s'l) and demonstrate
the kinetic competence of the elimination step.
Since no initial binding occurs, the observed rate of inhibition can be written as the combination of
rate constants given in the equation
^obs
=
ffl M ^elimination ' (^elimination + ^-l) (Eq 4).
where ki is the forward acylation of the enzyme and k.i is the reverse deacylation pathway. The
observation that the leaving group is released in a kinetically competent step without an induction
period during inactivation indicates that the acylated enzyme-inhibitor complex does not
accumulate prior to release of the leaving group. Therefore, the elimination step must be fast





k\, ifk_i is not significant.
44
Secondary deuterium isotope effects on inactivation.
I ,9 19 LG =same as 13
LG = CI&k-
I o o
Secondary deuterium isotope effects on inactivation kinetics were used to determine the
significance of k_i and establish the rate determining step of the inactivation pathway. HLE
inhibition by the isotopically labeled inhibitor 19 and the unlabeled inhibitor 13 were investigated
using stopped-flow to determine the effect of the deuterium substitution at a carbon that changes
hybridization along the proposed inactivation pathway. The inhibitors were solubilized using the
nonionic surfactant, Brij35, with the expectation of achieving larger signals and less second order
conditions for improved reproducibility of the observed rates. The highest concentration of
inhibitor 13 previously used in the BSA buffer system was at the solubility limit of the compound.
The kinetic data from a concentration series of inhibitor 13 in 0.1% Brij35 buffer system are given
in Table 5. These data clearly show that kjnactivatjon
= 3.0 X
104
M_1s_1 is dramatically different
Table 5: Stopped-Flow Kinetics of HLE inhibition in the presence of Brij35














from the 8.57 X 10
M1 s"1
second order rate constant for inactivation previously obtained in
0.1% BSA buffer system. Possible explanations for the discrepancy were explored.
It was thought that Brij35 may be a competitive inhibitor ofHLE and to address this issue the
phenol release from 14 and the substrate kinetics were reexamined in the Brij35 buffer system.
The substrate kinetics were unaffected by Brij35 indicating that Brij35 is not competitively
inhibiting elastase in these experiments. The rate of phenol release in Brij35 at two different
inhibitor concentrations (7 and 14 uM) is given in Table 6. The observation that the observed rate
of phenol release is depressed in Brij35 relative to BSA demonstrates that inhibitors 13 and 14
behave similarly in the Brij35 buffer system. In addition, the observed rate did not double with a 2
Table 6: Phenol Release in Brij35
Experimental Modeled assuming Ke*6.5uM soluble












Figure 20: Limited solubility model assumes that HLE does not react with inhibitor in
Brij35 micelles
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fold increase in inhibitor concentration in the presence ofBrij35, providing further evidence that
Brij35 is not a competitive inhibitor.
A limited solubility model is a possible explanation for the observed discrepancy in inactivation
rates. The enzyme may only be reacting with inhibitor in the aqueous phase of the Brij35-buffer
system while the remainder of the inhibitor may be trapped in the micelles in equilibrium (Figure
20). To explore this hypothesis, simulation of a limited solubility model was performed and
modeled with 6.5 uM limited solubility of the inhibitor. In this model only 6.5 uM of inhibitor is
soluble in the aqueous phase and available for reaction with enzyme. The expected observed rates
presented in Table 6 are 0.35 and 0.28 s~l according to this model and the second order rate
constant multiplied by K, is 5.4 X
104
M'^s'l. This is consistent with the decrease in the rate
constant observed with both 13 and 14. The numbers generated from a simulation of the limited
solubility model were used to do a slow binding kinetic fit to determine how the kinetics would
appear if inhibitor were reacting with enzyme in the aqueous phase and slowly siphoning in from
the Brij35 micelles. As shown in Figures 21 and 22, perfectly reasonable curves are obtained and
the limited solubility model displays reasonable kinetics at both inhibitor concentrations.
Therefore, Bij35 is not believed to be a competitive inhibitor of HLE because 1) the substrate
kinetics are unaffected by Brij35 and 2) a 2 fold increase in inhibitor concentration does not give a
2 fold increase in k0bs for phenol release. However, the limited solubility model does suggest that
the effective concentration of inhibitor is the only difference in the two buffer systems. There is no
evidence that the kinetics of inhibiton are operating by different mechanisms in the two buffer
systems.
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Figure 21 : Simulation of limited solubility model with fit to slow-binding kinetic equation
for [14] = 7 uM
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Figure 22: Simulation of limited solubility model with fit to slow-binding kinetic equation
for [14] = 14 uM
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The inactivation kinetics for the deuterated and nondeuterated compounds were determined under
identical conditions in the Brij35 buffer system. From 19 determinations of the nondeuterated
inhibitor a kODS
= 0.027 s_1 +/0.001 was obtained and from 8 determinations of the deuterated
compound a k0t,s
= 0.0268 s"1 +/- 0.0011 was obtained. The isotope effect ki^D
= 1007 +/"
0.055 corresponds to a secondary deuterium isotope effect of less than 1%. These results establish
with confidence that there is no secondary isotope effect on the inactivation kinetics.
The observed rate of inactivation was given above in Equation 4. The elimination step is the only
step that involves a change in hybridization of the deuterium substituted carbon during
inactivation. Hybridization changes from tetrahedral to trigonal
(sp3
to sp2) in the elimination step
and therefore, a secondary isotope effect on the observed inactivation kinetics would indicate that
the kgiinrinatjon term is part of the overall observed rate constant. If kgiimination is the rate







kelimination / k-l (EQ 5)
then becomes Equation 5. It is evident that the overall observed rate constant contains the
kelimination term m ^e numerator and therefore, a secondary isotope effect of kjj/k)
> 1.0
would be observed if kelimination >s rate determining. If kj is the rate limiting step and k_i is
kinetically significant, then k0Ds is a combination of all the rate constants given in Equation 4 and
again, due to the kgiimination term> an isotope effect would be observed. However, in the case







Tne keiimination term 1S no longer part of the overall rate constant and no secondary deuterium
isotope effect on the kinetics of inactivation would be observed (kjj
= kj)). Therefore, the lack of
an observed secondary isotope effect on inactivation is consistent with forward acylation of the
enzyme (kj) being the rate determining step of the inactivation pathway and deacylation (k_i) not
being kinetically significant.
Secondary deuterium isotope effect on reactivation kinetics.
The secondary deuterium isotope effect on reactivation kinetics was investigated using the
4-
isopropyl-6-methoxy chloromethyl compound (20) with deuterium substitution at a carbon that
changes hybridization along the proposed reactivation pathway. The observed rate of reactivation





k.3 / (k4 + k3) (Eq 7)
imine leading to the formation of the ring closed product and k3 is the proposed crosslinking of
the enzyme with histidine. The hybridization for steps k3 and k4 changes from trigonal to
tetrahedral
(sp2 to sp3) and therefore kj) > kjj. For k.3 the hybridization changes from
tetrahedral to trigonal and the isotope effect is kfj > kr> An overall isotope effect ofk^D > 1.0
would be consistent with k_3 being the rate determining step. Upon incubation, enzyme
inactivated with these inhibitors slowly reactivates. The return of HLE activity following
inactivation with both the deuterated and nondeuterated chloromethyl compounds is shown in
Figure 23. Duplicate determinations along with controls were made side by side under exactly the
same conditions and an isotope effect of 8%
+/- 5% was observed (kn/ko
= 108 +/- 0.05).
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Reactivation studies were performed at 23 C and complete reactivation (>95%) was observed.
This experiment is inconclusive and did not establish that an isotope effect exists with any
statistical confidence. Although it is likely that one does exist, multiple determinations of this
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The proposed mechanism of HLE inhibition by benzisothiazolinone-l,l-dioxides (Figure 16)
involves acylation of the active site serine followed by elimination of the leaving group. The
reactive imine intermediate formed by elimination can undergo hydration followed by deacylation
(kt) or it can react with an enzyme nucleophile (k3) to form a stable enzyme-inhibitor complex
that slowly reactivates (k.3). The following data support this proposed mechanism. The
observation that initial velocities in the presence and absence of inhibitor are identical establishes
that the reversible formation of a Michaelis complex does not occur prior to acylation of the
enzyme. The phenolic leaving group of compound 14 was released in a kinetically competent step
without an induction period and no secondary deuterium isotope effect on inactivation kinetics
was observed for compound 13. Assuming that compounds with different leaving groups follow
the same inactivation pathway, the lack of an observed isotope effect indicates that the rate
limiting step for the inactivation reaction is forward acylation (ki). Reactivation is independent of
leaving group variations and is complete. This observation is consistent with the formation of a
common intermediate enzyme-inhibitor complex and a common reactivation pathway through the
same rate determining step. The product of reactivation was identified as the ring closed product.
The observation that 30% of this product forms within 5 minutes and the remainder forms slowly
over 4 days is consistent with partitioning. The most likely alternate pathway is the reaction that
crosslinks the enzyme active site serine-195 and histidine-57 (k3). Although partitioning is
suggestive of crosslinking and the kinetically important k_3 step, no conclusive evidence was
presented in this investigation.
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As potential therapeutic agents, the benzisothiazolinone-1,1 -dioxides are potent, time-dependent,
reversible inhibitors ofHLE that demonstrate the ability to inhibit HLE catalyzed degradation of
insoluble elastin. A stoichiometry of 1.4 to 1.47 equivalents per mole of enzyme indicates that
these compounds are efficient inhibitors ofHLE. Their proposed mechanism of action differs from
a suicide inhibitor mechanism in that it has an important reactivation pathway (k.3) whereby the
enzyme regains full activity. Thus, this class of compounds may offer several advantages over
other types of HLE inhibitors. Considerable effort has been focused on the development of
synthetic, low molecular weight inhibitors as well as protein inhibitors of HLE as possible
therapeutic agents. Some protein inhibitors are commercially available. However, these
compounds have limited usefulness due to their expense and difficult administration. In
comparison to protein inhibitors, synthetic, low molecular weight inhibitors have the potential for
oral bioavailability. Of the synthetic inhibitors, potent, reversible inhibitors of elastase may have
the greatest therapeutic potential because they are less likely to react with other proteins or
nucleophiles in vivo. Therefore, the benzisothiazolinone- 1,1 -dioxide inhibitors of HLE appear
promising as useful therapeutic agents in the treatment of inflammatory pulmonary diseases.
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